Stock 2257 SIRNAOMICS LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Sirnaomics Ltd.

Equities

2257

KYG2050P1028

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:20 2024-05-14 EDT 		5-day change 1st Jan Change
7.65 HKD +5.37% Intraday chart for Sirnaomics Ltd. +1.06% -78.63%
05-10 Sirnaomics Ltd. Appoints Edward Yongxiang Wang as Executive Director CI
04-17 Sirnaomics Receives US FDA Guidance on Trials for Squamous Cell Carcinoma Treatment MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Sirnaomics Announces 2023 Annual Results
PR
Sirnaomics will Present its Innovative Dual-Targeted GalNAc muRNA Programs in 2024 OPT Conference
PR
Sirnaomics to Present Latest Developments of STP705 for Focal Fat Reduction at IMCAS World Congress 2024
PR
Sirnaomics Publishes Novel Mechanism of Action of RNAi Cancer Therapeutic STP707 for Solid Tumors
PR
Basal Cell Carcinoma Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 (Updated)
AQ
RNAimmune Receives Investigational New Drug Application Clearance from U.S. FDA for mRNA-Based Respiratory Syncytial Virus Vaccine RV-1770
PR
Sirnaomics Announces Successful Completion of Cohort 1 from Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Treatment
PR
Sirnaomics Promotes Francois Lebel, M.D. to Chief Medical Officer
AQ
Sirnaomics Promotes Francois Lebel, M.D. to Chief Medical Officer
PR
Sirnaomics Presents Positive Clinical Data of STP705 for Focal Fat Reduction
PR
Sirnaomics Announces Successful Phase I Clinical Study of RNAi Therapeutic STP707 for Treatment of Multiple Solid Tumors
PR
Sirnaomics Appoints Dr. Francois Lebel as Senior Vice President for Preclinical and Clinical Development
PR
Sirnaomics to Present Latest Developments on Two Proprietary Delivery Platforms at Upcoming Industry Conferences
PR
Sirnaomics Establishes a Strategic Partnership with EDIRNA Inc., an RNA-Editing Therapeutic Company
PR
Sirnaomics Advances STP705 for Squamous Cell Carcinoma In Situ into Late-Stage Clinical Development
PR
Sirnaomics Reports Interim Results of STP705 Phase I Clinical Study for Medical Aesthetics Treatment in Adults Undergoing Abdominoplasty
PR
Sirnaomics Dosed the First Patient in Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Treatment
PR
Sirnaomics to receive HK$8 million subsidy from the HKSTP Clinical Translational Catalyst Plan
PR
RNAimmune Receives FDA Clearance of Investigational New Drug Application for Phase 1 Trial of RV-1730 COVID-19 Booster Vaccine
PR
Sirnaomics Launches Phase I Clinical Trial for GalNAc Factor XI Program
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 2257 Stock
  4. News Sirnaomics Ltd.
  5. Press Releases
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW